Rapid Rx Quiz: Omega-3 Fatty Acids

Mary L. Windle, PharmD


August 25, 2022

Treatment of hyperlipidemia is the primary approved use of OM3FAs. In patients with triglycerides that are elevated (200-499 mg/dL) or very high (≥ 500 mg/dL), the AHA recommends 2-4 g/d of EPA or EPA plus DHA. The AHA concluded that prescription OM3FAs (eg, icosapent), as monotherapy or as an adjunct to other lipid-lowering agents, are an effective and safe option for reducing triglycerides at a dose of 4 g/d.

Learn more about hypertriglyceridemia.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.